Dilip Surana led Microlabs Limited Wins peoples heart, voted as Best Company to work for at Pharma Leaders 2016 annual power brand Awards.

Dilip Surana led Microlabs Limited Wins peoples heart, voted as Best Company to work for at Pharma Leaders 2016 annual power brand Awards.

Microlabs Limited voted by the jury members of the Network 7 Media Group’s annual pharmaceutical power brand awards in the category of Best Company to work for under the selection process of strong & robust HR policy aimed at building a world-class community of pharma professionals.

Microlabs received top recognition when the visionary CMD of Microlabs  Dilip Surana received the coveted award at the glittering annual award ceremony of Pharma Leaders Power Brand awards considered to be most credible & prestigious. The Trophy & Citations was received from the hands of Dr. Mukesh Batra, Chairman, Dr Batras & satya brahma, chairman & editor-in-chief, pharma leaders group where more than 400 industry leaders were present on friday, 23rd december 2016 at hotel sahara star.The set of 40 awards ware conferred to the top leaders & companies. Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications

DILIP-SURANA-_MICRO-LABS

With more than 9000 dedicated employees, 20 marketing divisions, 14 oral formulation plants with a strong R & D facility, the institution of Microlabs’s landmark & inspiring “Micro’s Performance Award”has been very exemplary. Indeed the employees continue to work as a one family & one team making Microlabs as India’s most respected pharma company with a formidable domestic marketing & strong export house. The growth of Microlabs has also been consistent over the last few years  & with among the top 10 companies like Cipla with  (20%), Mankind (21%), Alkem (28%), Macleods (30%), Lupin (24%) and Aristo (38%) grew faster &  Glenmark with  (26%), Micro labs (20%) and IPCA (27%) thus outpaced the market. Today Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centres that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast growing transnational healthcare organizations.

Ranking 14th among prescriptions (as per SMSRC May 16′ )and 19th in sales (as per AWACS MAT May’16) , Micro’s brand portfolio includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management.The company is also at the forefront in social contribution, striving to be a model corporate citizen in terms of Environmental Protection & Social Initiatives with significant contributions in the areas of education and health. Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2020.

The Jury Members strongly believes that Dilip Surana’s visionary leadership integrates the task orientation style and people orientation style of leadership in a qualitatively new level of performance. The Company has made people perform tasks because they are happy to do them as they are inspired by the vision of building a successful healthcare empire. Under Mr. Dilip Surana’s visionary leadership,  the entire workforce showed exceptional results and made them perform beyond their imagined limitations. They are  happy not only because their leader is the best but because they have become their best selves because of their leader. The strong 9000 employees bear testimony of Company’s vision that  “people are the main priority at our establishment. Company’s people are essential to Company’s success. Company’s focus on building their capabilities, and aim to support and empower them to be the best they can be. You have attracted and retained the most talented people by investing in training, development, support, and learning opportunities. You rightfully realize that all the technologies and facilities amount to nothing in the hands of an unskilled employee. This reason alone motivates you to provide the best of opportunities and work conditions to Company’s dedicated members. As a progressive healthcare company, helping Company’s employees stay safe, healthy and productive is a priority.

Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications. The theme of the Summit India@70, was presented by Annaswamy Vaidheesh, Managing Director – India & Vice President South Asia, GSK Pharmaceuticals India. Mr. Krishnakumar Subramaniam, Vice President, Business Development, India, Africa & Middle East, Glenmark Pharmaceuticals Ltd gave an opening Address & moderated the summit analyzing the speakers viewpoint.Satya Brahma,Chairman & Editor-In-Chief – Pharma Leaders Group in his opening address said “the change of guard in America with Donald Trump becoming US president, the impact of healthcare/pharma business will have a significant impact as Trump win might mean opportunities for Indian pharma.Trump had proposed to lift entry barriers for drug makers that offer safe, reliable and cheaper products. India contributes to nearly a third of all drugs sold in the US and this is unlikely to change for now, given the thrust of both Democratic and Republican parties on affordable health care. The US market will, however, continue to see pricing pressure as a result of consolidation of hospitals and insurance companies”. Increasing focus on Patients safety & concerns by hospitals & pharma companies will be key to healthcare innovations said Satya Brahma. The other notable speakers included Mr.Rajendra Pratap Gupta, Policy Maker, Researcher, & advisor to  Minister of Health & Family Welfare , Govt. of India addressed on “Digital Healthcare Innovations – Challenges & Opportunities”. The focus on healthcare delivery was evident as Health care in rural India– How technology can be leveraged for improving health care in Rural India was presented by Mayank Handhi, Social Activist in a interactive debate with Satya Brahma of Pharma Leaders. Dr. Manoj Khanna, Founder and Chairman, Enhance Clinics, Globally renowned Hair Transplant & Cosmetic Surgeon spoke on “Cosmetic Surgery Industry in India – Achi Din kya Aayenge?”. Vipin Pathak, Co- Founder & CEO, Care 24 addressed on Elder Care: Changing landscape, India and global. The highlight of the Summit at Pharma Leaders 2016 debate was on panel discussion moderated by Satya Brahma where top minds of the medical profession & healthcare addressed on “Is healthcare a commodity or a basic human need?”. The esteemed members of the panel discussion were Dr. Kishore Kumar, Consultant Neonatologist, Chairman,Cloudnine Hospital,Dr. Sudhansu Bhattacharyya, Head of Department of Cardiac Thoracic Surgery,  Bombay Hospital,Dr. Mudit Saxena, Group CEO Care Hospitals, Anand Garg, Former Chief Executive Officer, Seven Hills Health,Dr. Manoj Khanna, Chairman, Enhance Clinics,Dr. Debraj Shome, facial plastic surgeon and director, The Esthetic Clinics,Chandrashekhar Pandey – Founder and COO at Smile Merchants,Dr. Mannan Gandhi, Founder, The Integral Ayurveda,Rushi Trivedi – Founding Director & CEO at Smile Merchants

Annaswamy Vaidheesh, Dr. Manoj Khanna, Dr. Sudhansu Bhattacharya, Dr Huzaifa Khorakiwala, Binish Chudgar, Rajendra Gupta among others awarded at pharma leaders 2016 annual pharma leaders power brand awards

Annaswamy Vaidheesh, Dr. Manoj Khanna, Dr. Sudhansu Bhattacharya, Dr Huzaifa Khorakiwala, Binish Chudgar, Rajendra Gupta among others awarded at pharma leaders 2016 annual pharma leaders power brand awards

Pharma Leaders 2016 power brand awards conferred to top companies & accomplished healthcare leaders

Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications. The theme of the Summit India@70, was presented by Annaswamy Vaidheesh, Managing Director – India & Vice President South Asia, GSK Pharmaceuticals India. Mr. Krishnakumar Subramaniam, Vice President, Business Development, India, Africa & Middle East, Glenmark Pharmaceuticals Ltd gave an opening Address & moderated the summit analyzing the speakers viewpoint.

Best CSR in Pharma 2016Best Hair Transplant Surgeon in india 2016Biotech Leader of the DecadeBusiness Leader of the year 2016CEO of the year 2016Clinical Leader of the Year 2016Contract Manufacturing Company of the year 2016Dynamic Enterprise of the Year 2016Dynamic Entrepreneur of the year 2016Dynamic Women Entrepreneur of the Year 2016Emerging Pharma Leader of the 2016Global ParliHealthcare Leader of the Decade - CopyHealthcare Leader of the DecadeIndia’s Most Admired & Valuable Dental Clinic 2016 - smileIndia’s Most Admired Hospital Chain in Value & Customer Satisfaction 2016India’s Most Admired Neonatologist 2016 -India’s Most Admired Surgeon 2016India’s Most Promising Eye Care Hospital 2016India’s Most Promising Healthcare TPA of the Year 2016 - good healthIndia’s Most Promising Healthcare TPA of the Year 2016 - vidalIndia’s Most Promising Home Healthcare Service Provider 2016 - Care 24India’s Most Promising Home Healthcare Service Provider 2016 - India HomeIndia’s Most Promising Orthopedic Surgeon of the Year 2016 - CopyIndia’s Most Promising Orthopedic Surgeon of the Year 2016India’s Most Valuable & Admired Health Insurance Company 2016India’s Most Valuable LEED Platinum Certified HospitalInnovative Face in Cosmetic Dermatology 2016Inspiring Business Leader of the Year 2016 - CopyInspiring Business Leader of the Year 2016Most Promising & Innovative Cosmetic Clinic 2016 - CopyMost Promising & Innovative Cosmetic Clinic 2016Most Promising Dental Healthcare Service Provider 2016Most Valuable Youngest Dermacare company 2016Pharma Leader Executive of the Year 2016Pharma Professional of the YearVisionary Entrepreneur of the YearWoman Healthcare Leader of the Year 2016

Satya Brahma,Chairman & Editor-In-Chief – Pharma Leaders Group in his opening address said “the change of guard in America with Donald Trump becoming US president, the impact of healthcare/pharma business will have a significant impact as Trump win might mean opportunities for Indian pharma.Trump had proposed to lift entry barriers for drug makers that offer safe, reliable and cheaper products. India contributes to nearly a third of all drugs sold in the US and this is unlikely to change for now, given the thrust of both Democratic and Republican parties on affordable health care. The US market will, however, continue to see pricing pressure as a result of consolidation of hospitals and insurance companies”. Increasing focus on Patients safety & concerns by hospitals & pharma companies will be key to healthcare innovations said Satya Brahma. The other notable speakers included Mr.Rajendra Pratap Gupta, Policy Maker, Researcher, & advisor to  Minister of Health & Family Welfare , Govt. of India addressed on “Digital Healthcare Innovations – Challenges & Opportunities”. The focus on healthcare delivery was evident as Health care in rural India– How technology can be leveraged for improving health care in Rural India was presented by Mayank Handhi, Social Activist in a interactive debate with Satya Brahma of Pharma Leaders. Dr. Manoj Khanna, Founder and Chairman, Enhance Clinics, Globally renowned Hair Transplant & Cosmetic Surgeon spoke on “Cosmetic Surgery Industry in India – Achi Din kya Aayenge?”. Vipin Pathak, Co- Founder & CEO, Care 24 addressed on Elder Care: Changing landscape, India and global. The highlight of the Summit at Pharma Leaders 2016 debate was on panel discussion moderated by Satya Brahma where top minds of the medical profession & healthcare addressed on “Is healthcare a commodity or a basic human need?”. The esteemed members of the panel discussion were Dr. Kishore Kumar, Consultant Neonatologist, Chairman,Cloudnine Hospital,Dr. Sudhansu Bhattacharyya, Head of Department of Cardiac Thoracic Surgery,  Bombay Hospital,Dr. Mudit Saxena, Group CEO Care Hospitals, Anand Garg, Former Chief Executive Officer, Seven Hills Health,Dr. Manoj Khanna, Chairman, Enhance Clinics,Dr. Debraj Shome, facial plastic surgeon and director, The Esthetic Clinics,Chandrashekhar Pandey – Founder and COO at Smile Merchants,Dr. Mannan Gandhi, Founder, The Integral Ayurveda,Rushi Trivedi – Founding Director & CEO at Smile Merchants

Here are the List of Winners at the Pharma Leaders 2016 Power Brand Awards


Business Leader of the year 2016

Mr.Binish Hasmukh Chudgar,Vice Chairman & MD,Intas Pharmaceuticals Limited

Business Woman of the year 2016

Ms.Ameera Shah,Promoter & MD, Metropolis Healthcare

Emerging Pharma Leader of the 2016

Mr. Sandeep Singh,Jt.Managing Director,Alkem Laboratories Ltd.

Best Company to Work For  2016

Microlabs Limited

CEO of the year 2016

Mr. Prabhat Agarwal,CEO, Alkem Labs Ltd

India’s Most Valuable & Admired Health Insurance Company 2016

Star Health and Allied Insurance Co Ltd

India’s Most Promising Face in Diet & Nutrition 2016

Ms.Kinita Kadakia Patel,Founder,MEALpyramid

India’s Most Promising Home Healthcare Service Provider 2016 ( Joint Winners)

India Home Health Care

Care 24

Dynamic Entrepreneur of the year 2016

Dr. Akshay Batra,Managing Director, Dr. Batra’s

Dynamic Enterprise of the Year 2016

Syngene International Ltd

Innovative Woman CEO of the year 2016

Dr Rupali Basu, President and CEO(ER), Apollo Hospital Group

Innovative Face in Cosmetic Dermatology 2016

Dr.Simal Soin, Founder & Cosmetic Dermatologist,Aayna

Pharma Professional of the Year 2016

Mr.Rami Reddy Gundala, Managing Director, Adcock Ingram Limited

Emerging Company of the Year 2016

Bioderma India

Pharma Leader Executive of the Year 2016

Mr.Ambarish Chatterjee,General Manager,Laboratorie Bioderma

Dynamic Women Entrepreneur of the Year 2016

Dr.Reema Das Mallik,Director And Founder, Illumis Aesthetic Clinic

Clinical Leader of the Year 2016

Veeda Clinical Research

Woman Healthcare Leader of the Year 2016

Ms.Ranjeeta Vinil, Founder Director, Saarathi Healthcare Pvt Ltd

India’s Most Promising Healthcare TPA of the Year 2016

Good Health TPA Services Ltd

Vidal Health TPA Private Limited

Most Promising Dental Healthcare Service Provider 2016

DentCare Dental Lab Pvt.Ltd

India’s Most Admired & Valuable Dental Clinic 2016

Smile Merchants, The Dental Clinic

India’s Most Promising Eye Care Hospital 2016

Asian Eye Hospital and Lasik Laser Institute

Biotech Leader of the Decade

Mr.C L.Rathi, Managing Director, Advanced Enzyme Technologies Ltd

Best CSR in Pharma 2016

Wockhardt Foundation

Healthcare Leader of the Decade

Mr. Rajendra Pratap Gupta, Advisor to Health Minister, Government of India

India’s Most Promising Hospital of the Year 2016

Sunshine Hospitals

India’s Most Promising Orthopedic Surgeon of the Year 2016

Dr. A. V. Gurava Reddy, Managing Director & CEO, Sunshine Hospital

Pharma Professional of the Decade

Mr. Annaswamy Vaidheesh, MD, Glaxosmithkline Pharmaceuticals Limited

Most Promising & Innovative Cosmetic Clinic 2016

The Esthetic Clinics

Best Hair Transplant Surgeon in india 2016

Dr. Manoj Khanna, Founder and Chairman, Enhance Clinics

Contract Manufacturing Company of the year 2016

Adcock Ingram Limited

India’s Most Valuable LEED Platinum Certified Hospital

Kohinoor Hospital

India’s Most Admired Neonatologist 2016

Dr. Kishore Kumar, Chairman, Cloudnine Hospital

India’s Most Admired Hospital Chain in Value & Customer Satisfaction 2016

Cloudnine Hospital

Visionary Entrepreneur of the Year

Mr. Sujit Kumar Singh, CMD, Shreya Lifesciences Limited

India’s Most Admired Surgeon 2016

Dr. Sudhansu Bhattacharya

Most Valuable Youngest Dermacare company 2016

Adroit Biomed Limited

Inspiring Business Leader of the Year 2016

Sheel Kumar Singh, Director, Shreya Group

Innovative Healthcare Initiatives in Providing Community Healthcare by Apollo Group

 Dr.Sandeep Chatrath, Regional Chief Executive Officer, Apollo Hospitals


Rated & widely acclaimed by the industry experts & analysts as a credible award platform known for selecting top leaders through a meticulous methodology & stringent selection process involving research inputs & credible voting process by noted eminent juries, pharma eaders today is india’s only dedicated celebration of excellence in healthcare innovation, pharmaceutical & medical excellence and brand transformation. Pharma Leaders™  as you will be  aware since its inception in 1999, has so far awarded more than 800 top pharma entrepreneurs, medical professionals, research scientists & government academia.

Shreya Life Science ends 2016 with Double Awards, founder Chairman Sujit Singh voted as “Visionary Entrepreneur of the Year” while dynamic Sheel Kumar Singh was awarded as “Inspiring Business Leader of the Year 2016” at Pharma Leaders Power Brand Awards

Shreya Life Science ends 2016 with Double Awards, founder Chairman Sujit Singh voted as “Visionary Entrepreneur of the Year” while dynamic Sheel Kumar Singh was awarded as “Inspiring Business Leader of the Year 2016” at Pharma Leaders Power Brand Awards

The dynamic duo of Shreya Life Sciences both Sujit Singh & Sheel Singh shined at asia’s most prestigious annual healthcare awards 2016 for outstanding & dynamic leadership in steering Shreya’s business both domestic, international & contract manufacturing business.

sheelsujit

Mumbai based Shreya Life sciences, one of the fastest growing pharma company with a turnover of more than 500 crore having strong presence in domestic market & formidable overseas  presence specially in CIS countries received top recognition when the founder chairman of the company Sujit Kumar Singh & Director of the shreya group Sheel Kumar Dhananjay Singh were awarded at the glittering annual award ceremony of Pharma Leaders Power Brand awards considered to be most credible & prestigious. The Trophy & Citations was received from the hands of Dr. Mukesh Batra, Chairman, Dr Batras & satya brahma, chairman & editor-in-chief, pharma leaders group where more than 400 industry leaders were present on friday, 23rd december 2016 at hotel sahara star.The set of 40 awards ware conferred to the top leaders & companies. Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications

The institution, Pharma Leaders honors the principles and prominent leadership of the healthcare global leaders, decision makers, and various organizations that are path breakers of leadership excellence. It focuses on the remarkable achievements & noteworthy influence of the pharma leaders, and also throws light on the pivotal role played by the iconic healthcare leaders in leading the healthcare transformation to the threshold of the new world. It aims to make a quantum leap and a comprehensive approach in the performance of all those have contributed immensely to make their vision a great success, and who were able to take the maximum advantage of the opportunities available to them regionally and internationally and making the best out of those opportunities.


About Shreya Life Sciences

Shreya Life Sciences, the Indian arm of Shreya Group started its operations in India in the year 2001 by acquiring the Pharma Division of Rallis India Ltd., a TATA Group company. In 2003, Shreya acquired the domestic pharma business of Plethico Pharmaceuticals Ltd., with a view to achieve a full-fledged national presence. Shreya Life Sciences Pvt., Ltd. engages in the distribution of medicaments and medical products. The company sells its products ranging from anti-spasmodics and insulin to drugs for rheumatic arthritis. The company was incorporated in 1991 and is based in Mumbai, India. Shreya Life Sciences Pvt., Ltd. operates as a subsidiary of Shreya Corporation PJSC. Shreya Corporation currently boasts of distributing widest range of medicaments and medical products, including more than 4,500 medicines of all pharmacological groups. The company has direct contacts with more than 300 pharmaceutical enterprises among which there are the largest national and foreign manufacturers. Shreya is an agent for some of top MNCs like GSK, Merck, Aventis, and Sanofi Synthelabo. It has also partnered for Indian companies like Ranbaxy ( Now Sun Pharma ), Dr. Reddy’s Labs and JB Chemicals in Russia. Mumbai headquartered Shreya Life Sciences today generates revenue of more than Rs 500 crore turnover, of which more than one-third proportion has been from the company’s exports to the parent company in Russia


Strategic Alliances

  • Shreya has strategic alliance with Bio Technology General Corporation, USA,
  • through SciGen, Singapore and Scitech USA to import and market Recombinant Human
  • Insulin, Hepatitis B Vaccine & Growth Hormone (BTGC acquired by Ferring).
  • License agreement with Bioton, Poland, to import Recombinant Human Insulin Crystals and finished formulation of Recombinant Human Insulin Cartridges through SciGen.
  • License agreement with Biotech GmBH, Germany (BBT) to market Gonadotropins in India.
  • License agreement with Generex Biotechnology Corporation, Canada / USA to distribute and market Oral Recosulin, ‘Oral-Lyn’ on an exclusive basis in Indian sub-continent which includes India, Nepal, Pakistan, Bhutan, Bangladesh, Srilanka & Myanmar .
  • Licence agreement with Lallemand and Institute Rosell, France, to market Probiotics.

 

 14633637_1275635705809120_8191540918190516958_o15723610_1275635225809168_6709764812268232500_o15723743_1275635909142433_6156336237960011838_o

Unmesh Joshi Led Kohinoor Hospital voted as “India’s Most Valuable LEED Platinum Certified hospital” at Pharma Leaders Power Brand Annual Awards 2016

Unmesh Joshi Led Kohinoor Hospital voted as “India’s Most Valuable LEED Platinum Certified hospital” at Pharma Leaders Power Brand Annual Awards 2016

 Kohinoor Hospital selected by the Pharma Leaders Jury for being the first & only Hospital in Asia & Second in the World  to have LEED Platinum Certified hospital

Monday,26th December 2016, Mumbai, Maharashtra, India. Mumbai based Kohinoor Hospital received a rare recognition at the most prestigious Pharma leaders power brand  annual awards organized by asia’s most analytical news media in healthcare communications in the very coveted category of “India’s Most Valuable LEED Platinum Certified hospital” at the 9th Annual pharmaceutical leadership Summit & Pharma Leaders business leadership awards 2016 in Mumbai on Friday,23rd December 2016. More than 350 healthcare leaders of the country were present in full attendance to witness the biggest & most awaited healthcare event of the yesar 2016.

Kohinoor Hospital, VidyaviharKohinoor Hospital, Vidyavihar15732658_1275633625809328_8874040050260782021_o15732629_1275635412475816_3738731414829840800_o15732591_1275633919142632_8309485283717848820_o15724868_1275634315809259_3801939141132029945_o15723797_1275637699142254_5608462995797437487_o

kohinoor

Rated & widely acclaimed by the industry experts & analysts as a credible award platform known for selecting top leaders through a meticulous methodology & stringent selection process involving research inputs & credible voting process by noted eminent juries, pharma leaders today is india’s only dedicated celebration of excellence in healthcare innovation, pharmaceutical & medical excellence and brand transformation. Team Kohinoor Hospitals received the Trophy & Citation from the hands of Dr. Mukesh Batra, Chairman, Dr Batras & Mr. Satya Brahma, Chairman & Editor-In-Chief, Pharma Leaders Group.

About Kohinoor Hospital

Kohinoor Hospital is Asia’s first LEED Platinum Certified hospital and the world’s second LEED Platinum Certified hospital.  One of the top hospitals in India and recognised among the best hospitals in Mumbai, Kohinoor Hospital is equipped with the latest technology, expert healthcare professionals and top-notch medical equipment, making it a world-class player in healthcare.This multi specialty hospital in Mumbai is centrally located and is easily accessible in time of emergencies. An aspect that continues to play an important role, when it comes to the great number of lives Kohinoor Hospital has saved. The best healthcare hospital becomes the obvious choice when illness strikes. Kohinoor Hospital is a one stop specialty hospital in Mumbai, India, for all your healthcare needs. All the necessities of comfort, continuity and consistency for good health are met without running between clinics and doctors anymore.


Super Specialty Centres

The hospital has set up multiple Centres of excellence in specialised healthcare; like Cardiology, Neuroscience, Orthopaedics, Critical care, Minimal Invasive Surgery and other unique disciplines; so diagnosis and treatment can be prompt and precise. Our super specialty centres include

Centre  for Critical Care Centre of Pulmonology & Sleep Studies
Centre  for  Cardiac Care Centre For Urology
Centre for Stroke Care Centre for Spine Care
Centre  for Cancer Care Super Speciality ENT Care & Research Centre
Centre for Bone & Joint Care Centre for Eye Care
Centre For Mother & Baby Care Department of Dental Care
Centre for General Surgery  & Minimal
Invasive Surgery
Department of Physiotherapy and Sports Medicine
Department of Dietetics and Wellness Advanced Diagnostic Centre

Effective treatment begins with the right diagnostics. Kohinoor Hospital is fully equipped with Advanced technologies and medical devices.

Following Facilities make it the Best Quality Hospital. 

24 Hour Cardiac Ambulance
24 Hour Radiology and Imaging with CT/MRI Scan
S.I.C.U./I.C.C.U.
N.I.C. U./ P.I.C.U .
Cardiac Diagnostics
2D Echo with Colour Doppler /Stress Test /TMT
Blood Bank and Pathology Lab
Microbiology Lab
Picture Archiving and Communication System (PACS) for Speedy Diagnosis
24 Hour Pharmacy
Ultrasonography & Colour Doppler
Dialysis Unit
State-of-the-art Operation Theatres with Laminar Air Flow, Hepa Filter & HVAC system
Custom-designed LDRP Suite
PFT
Catheterization Lab
3,300 Investigations – From Routine Checks to Special Tests
OPG
Sound Proof Audiometry Room
Sleep Study lab
Day Care Centre

 

 

 

Chandrakant Rathi of Advanced Enzyme Technology to receive the prestigious “Biotech Leader of the Decade” at Pharma Leaders 2016 Annual Power Brand Awards

Chandrakant Rathi of Advanced Enzyme Technology to receive the prestigious “Biotech Leader of the Decade” at Pharma Leaders 2016 Annual Power Brand Awards

 The veteran entrepreneur led Advanced Enzyme as a global leader in healthcare & nutrition & Bio Processing, 400+ proprietary products developed from 60 indigenous enzymes made Rathi as undisputed leader in enzyme research & complex enzyme eco-friendly solutions

 Chandrakant Laxminarayan Rathi, founder, promoter of Advanced Enzyme Technologies Ltd ranked among the top 15 global companies in terms of enzyme sales having more than 700 customers spanning presence across 50 countries worldwide, has been voted by the pharma leaders board as Biotech Leader of the decade at the 9th Annual pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2016 in Mumbai on 23rd December 2016 organised by Pharma Leaders, india’s oldest & Asia’s most analytical news media in healthcare communications.

Announcing the name of Chandrakant Laxminarayan Rathi, Satya Brahma, Chairman of Pharma Leaders Group stated that, “the rise of Advanced Enzyme as a global leader is primarily driven by Chandrakant Rathi’s visionary leadership & deep understanding of the enzyme market both in india & abroad & offering customized eco-friendly enzyme solutions. With close to nearly four decades in the market, Rathi has been phenomenally successful since 1989. Rathi has demonstrated exceptional entrepreneurial skill as a strong & aggressive biotech leader propelling the company to a successful listed company in 2016  which recently enjoyed a spectacular IPO, further consolidated the market by acquiring  70 per cent stake in JC Biotech, an active pharmaceutical ingredients manufacturer”. The company will now have an added advantage of a dominant leadership in API Serratiopeptidase, which is an anti-inflammatory enzyme, will make company a competitive edge along with flexibility in production.

clrathi

The coveted & prestigious title “Biotech Leader of the Decade “would be conferred to Chandrakant Rathi in a power packed presence of more than 350 healthcare leaders at Pharma Leaders 2016 annual award ceremony. The event will also felicitate 30 top pharma healthcare companies & industry leaders in a glittering award ceremony. Chandrakant Laxminarayan Rathi, Promoter and Managing Director, Advanced Enzyme Technologies holds a Bachelor‘s degree in Science (Chemical Engineering) from National Institute of Technology, Rourkela. He has over 37 years of experience in the enzyme industry and was one of the co-founders of Rathi Papains Private Limited incorporated in the year 1978, which was engaged in the business of manufacturing of enzymes from papain. In the year 1986, he joined Messrs Super Organic Research Laboratories as a partner till the year 1987 (which came to be acquired by the Company at a later stage). Subsequently, he promoted and incorporated the Company in the year 1989 and is currently responsible for the management of the entire operations of the Company and its Indian subsidiaries, including strategic initiatives of our businesses.

Noted Plastic Surgeon Dr. Debraj Shome voted as India’s Most Promising Face In Plastic Surgery Innovations 2015 at ILC Power Brand 2015

Amidst an audience of esteemed panelists and industry experts, Dr. Debraj Shome, renowned Mumbai-based plastic surgeon was awarded the title “Most Promising Face in Plastic Surgery Innovations”, at the India Leadership Conclave 2015. At the flagship event of the Network 7 Media Group, the award was presented during a stellar function held at Hotel Sahara Star late last week.

The award was announced to acknowledge Dr. Shome’s outstanding contribution to the medical industry over the last fifteen years, especially in Ophthalmic Plastic Surgery and Facial Plastic Surgery. A jury of industry thought-leaders and experts cast their votes to award the title to Dr. Shome for fantastic results and patient-focused delivery, which he is world-renowned for.

Dr. Shome has been significantly responsible for creating medical miracles in the plastic surgery space, offering nothing less than perfection to patients who seek treatment not only for aesthetic appeal, but also importantly for corrective surgeries after accidents. Regardless of the nature of the need, Dr. Debraj’s skill and rigorousness has ensured a remarkable reputation, as well as strong recommendations.

From a research standpoint, Dr. Debraj has spearheaded ground-breaking studies that make cost-effective plastic surgery and therapy available and accessible in the country. With a flawless track-record of delivering beauty through surgical and non-surgical procedures, Dr. Debraj is today one of the most sought-after facial plastic-surgeon amongst celebrity circles. Dr. Shome is also a columnist on leading publications including the Times of India, Hindustan Times and Daily News & Analysis (DNA), where he shares his thoughts on the future of plastic surgery, and upcoming innovations.

This is not the first time that Dr. Debraj’s contribution has been commended by the industry. With over 20 national and international peer-reviewed publications and several distinguishing awards, Dr. Shome has a distinguished track-record and reputation for excellence in healthcare delivery. In the year 2010, Dr. Shome was awarded the Colonel Rangachari Gold Medal and the Hanumantha Reddy Award 2010 by the Indian Ophthalmological society. In fact, Dr. Debraj was also the first Indian and the youngest individual to ever receive the Davies foundation Grant Award by the Royal College of Surgeons, Glawgow.

Dr. Debraj Shome comes with an outstanding list of accomplishments in a variety of medical areas including cancer-care and plastic surgery, with a specialization in Ophthalmic Oncology, Ophthalmic Plastic Surgery and Facial Plastic Surgery. He was part of the two-member team that invented a molecule QR 678 that helps patients grow back hair, without a need for transplants revolutionizing the way we looked at baldness problems. In cases of plastic surgery, he has been known to deliver excellent results right from facial reconstruction to a creative approach of using fillers to adjust bone-structure.

In his expert capacity, Dr. Shome has been associated with the Institute for Aesthetics and Cosmetic Surgery at Apollo Hospitals, Hyderabad, India, the Department of Facial Plastic Surgery at Aditya Jyot Eye Hospital, Mumbai, as well as the Tata Memorial Hospital in Mumbai. Shortly afterwards, he conceptualized a chain of aesthetic surgery centers called The Esthetic Clinic, in collaboration with the Apollo Hospital group. Dr. Debraj Shome is now a much sought after facial plastic surgeon in Mumbai and is a Consultant at Saifee Hospital, Apollo Spectra Hospital and the iconic Breach Candy Hospital.Being a motivated entrepreneur and an ardent advocate of second opinion, Dr. Shome launched his newest venture, MediAngels.com aims at providing patients with a digital platform to connect and interact with over 400 super-specialists globally, across over 96 specialty areas. As part of the Leadership Conclave, MediAngels.com was named “Emerging Online Healthcare Delivery Company of the Year 2015”.At the Indian Leadership Conclave, more than 300 industry leaders, diplomats, policy makers, social activists, business tycoons, rebel leaders including delegates from the Middle East, Europe & ASEAN countries were present. The panel felicitated leaders & companies across industry sectors, for remarkable their performances and making India proud & prosper.As part of the event, Dr. Debraj also delivered the keynote address, stating his vision for the healthcare sector in India titled – India@68 – Healthcare Delivery in India – Vision 2020. Providing a thoughtful and insightful leadership experience to the audience that comprised industry leaders as well as entrepreneurs, he spoke about the need for healthcare and medical professionals to embrace new-age ideologies and technology. To tackle the challenges of primary and specialty healthcare delivery, and make quality service available and affordable, he emphasized, it is essential to use technology effectively.

Pharma & healthcare leaders, policy makers to address on “india @ 70, patient first” at the historic pharma leaders 2016!

Pharma & healthcare leaders, policy makers to address on “india @ 70, patient first” at the historic pharma leaders 2016

Mumbai to host 9th annual pharmaceutical leadership summit & pharma leaders business leadership awards 2016, visionary pharma leaders to review healthcare progress & reforms post independence.

Pharmaleaders, asia’s most analytical news media in pharmaceutical & healthcare communications today announced the much awaited & prestigious healthcare event of the calendar year 2016, the 9th annual pharmaceutical leadership summit & pharma leaders business leadership awards 2016 to be held in Mumbai on Friday,the 23rd december 2016. Pharma Leaders 2016 is debating on the theme “India@70, Patient First” where the nation’s top leaders on healthcare, pharmaceutical, biotechnology will gather to listen from the healthcare thought leaders. Pharma Leaders vision 2016 Summit centers around the challenges of the accessibility, availability & affordability of healthcare in a country of billion population where the majority of the stakeholders, the vulnerable sections of the society are often deprived of basic healthcare. As the nation powers to stake its claim as a nuclear & defense power in the world, healthcare remains a big question mark. The $26 billion Indian pharmaceutical industry aiming to be on to be among the top 3 pharma markets by 2020, is expected to reach USD 55 billion in the next four years. Growing at a pace of 17.90 percent CAGR,the market size has expanded to USD 36.7 billion in 2016 from USD 6 billion in 2005. India is also the largest provider of generic drugs and has 20 percent global exports in terms of volume. Healthcare Policy is meant to empower patients & hence the reforms must be patient centric with focus on compassion, quality, integrity and respect, the release stated.

“India today is standing on the threshold of enormous opportunities where the global market is looking at us with much seriousness to invest & do business than ever before, the domestic healthcare scenario though presents serious challenges as patients safety & quality healthcare with affordable price has become a subject of tremendous concern. We as a nation must understand that healthcare is key to nation building, like defence, healthcare sector must be given a topmost priority”, Said Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders Group while announcing the 9th annual edition of Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2016.

“Patient-centered care has now made it to center stage in current discussions of quality & patient care. Pharmaceutical Companies, Government & healthcare practitioners therefore must ensure that patient-centric healthcare delivery system is key to growth & there should be greater focus on patient satisfaction and engagement. Healthcare provider must focus on consumers in a way that encourages them to seek all care within the system, optimizing care management and patient engagement. While companies & hospitals are measured on their success through revenue and profit in recent times, the success also should be on compassionate healthcare & initiatives must focus on medical facilities to reduce patient suffering and meet patient needs”.

More than 350 industry leaders, Policy makers, healthcare visionaries, political leaders, social activists, eminent doctors will be attending the historic pharma leaders 2016 in mumbai. Top voices from the pharmaceutical & healthcare leaders will be addressing the gatherings on topics of tremendous significance. Healthcare reforms, patient care, insurance, pricing, medical tourism, regulatory challenges, hospital management, digital healthcare, start-up healthcare are some of the key debates that will be deliberated in the summit proceedings. Pharma leaders power brand awards will also be conferred to the deserving companies & individual titles in more than 30 categories in the 9th annual pharmaceutical leadership awards 2016 in a glittering award night.

For further details on Registration, please cntact :

Network 7 Media Group

Plot 5, NS Road No. 12

Opposite Crepe station, JVPD, Juhu Scheme

Mumbai, Maharashtra, Pin 400049.

Email : debashish.mishra@network7mediagroup.com

URL : www.pharmaleaders.tv

Cell : ++ 91 8097667782

Web : www.pharmaleaders2016.com

www.pharmaleaders2015.com , www.pharmaleaders2014.com , www.pharmaleaderspowerbrand.com

 

Top Pharma Companies Cipla, Sun Pharma, Mankind, Glenmark, Zydus Cadila, Alkem among final nominees at Pharma Leaders 2016

Top Pharma Companies Cipla, Sun Pharma, Mankind, Glenmark, Zydus Cadila, Alkem among final nominees at Pharma Leaders 2016

Pharma Leaders 2016 announces nominees in the first set of categories at asia’s most prestigious 9th annual pharmaceutical leadership summit & pharma leaders business leadership awards 2016. Winners will be announced at leadership awards in 23rd December

Pharma Leaders, the flagship healthcare media company of Network 7 Media Group announced the first set of nominations at the industry’s much awaited leadership event, the 9th Annual Pharmaceutical leadership summit & pharma leaders business leadership awards 2016 to be held in Mumbai on 23rd December. The annual edition of pharma leaders final nominee selections has mixed names of both established companies as well as companies performing exceedingly well outside the purview of the media glare. Certain new categories in this year has been added in the field of Contract Research, Dental Clinics, Pharma Diagnostics etc. Pharma Leaders 2016 Summit is also deliberating a high powered debate on the theme “India @ 70, Patient First”. More than 300 industry leaders will be attending the annual celebration.

“Pharma Leader Jury arrive at the final six nominees for their leadership position in their respective fields after a meticulous scrutiny & a detailed research by a team of researchers & experts that are followed year after years at the pharma leaders annual award editions thereby making the process very credible & transparent. We are often asked by the nominees, as they are surprised when they see their name in the list of the final countdown. It is also a matter of great satisfaction & pride for the final six nominees even to make it to the top six nominations irrespective of the results of the final winner which will be declared on friday,the 23rd december 2016 at the grand award ceremony where more than 300 leaders of the industry are expected to make it to witness the most happening healthcare event of the year”, said Satya Brahma, Founder Chairman of the Pharma Summit 2016 organizing committee.Our attempt is to bring the leaders & companies who have been working remarkably well in tough conditions without financial aids in their respective field, without any public recognitions & media glare, this is the area of innovations where pharma leaders power brand awards make the difference, said Satya Brahma in the news release.

The nominees of the 9th annual pharmaceutical leadership summit & pharma leaders business leadership awards 2016 are as follows.

Business Leader of the year 2016

And the Nominees are

  1. Mr Nilesh Gupta,Managing Director, Lupin Limited
  2. Mr.Sharvil P. Patel,Deputy Managing Director,  Cadila Healthcare Limited.
  3. Mr.Kallam Satish Reddy,CMD, Dr. Reddy’s Laboratories
  4. Dr.B. S. Ajai Kumar, Chairman & CEO, HealthCare Global Enterprises Ltd
  5. Mr.Rajeev Juneja, MD, Mankind Pharma Limited
  6. Mr.Binish Hasmukh Chudgar , Vice Chairman & MD, Intas Pharmaceuticals Limited

Business Woman of the year 2016

And the Nominees are

  1. Ms.Tara Singh Vachani, CEO & Managing Director,Antara Senior Living
  2. Ms.Vinita Gupta, Chief Executive Officer Lupin Limited
  3. Ms.Kanchan Naikawadi,Promoter Director, Indus Health Plus
  4. Ms.Zahabiya Khorakiwala,Managing Director at Wockhardt Hospitals
  5. Ms.Ameera Shah,Promoter & MD Metropolis Healthcare
  6. Ms.Alisha Moopen, Executive Director & CEO – Aster DM Healthcare

Emerging Pharma Leader of the 2016

And the Nominees are

  1. Mr. Anand Piramal,Executive Director, Piramal Group
  2. Dr. Murtaza H. Khorakiwala, Managing Director, Wockhardt Limited.
  3. Mr. Yogesh Agarwal, Managing Director, Ajanta Pharma Limited.
  4. Mr. Sandeep Singh, Jt MD, Alkem Labs Ltd.
  5. Mr. Arjun Juneja, Director, Mankind Pharma Ltd.
  6. Mr.Adar Poonawalla,CEO, Serum Institute of India

 India’s Most Admired Pharmaceutical Company of the year 2016

And the Nominees are

  1. Mankind Pharma Limited
  2. Glenmark Pharmaceuticals Limited.
  3. Lupin Limited.
  4. Cipla Limited.
  5. Sun Pharmaceutical Industries Ltd
  6. Biocon Limited.

Best Company to Work For  2016

And the Nominees are

  1. Cipla Limited
  2. Pfizer India Limited
  3. Sun Pharmaceutical Industries Ltd
  4. Abbott India Limited
  5. Microlabs Limited
  6. Cadila Healthcare Limited

Most Promising Dental Healthcare Service Provider 2016

And the Nominees are

  1. DentCare Dental Lab Pvt.Ltd
  2. Chesa Dental Care Service Limited
  3. Today’s Healthcare India Pvt. Ltd.
  4. Dr. Suhas Lele Smiles Forever
  5. Rajan Dental Institute
  6. Dentzz Dental

CEO of the year 2016

And the Nominees are

  1. Mr. Rajit Mehta, Managing Director & CEO – Max Healthcare
  2. Mr. Umang Vohra, Managing Director & Global CEO, Cipla Ltd.
  3. Mr. Sheetal Arora, Managing Director, Mankind Pharma Ltd.
  4. Dr. Arun Chandavarkar, CEO & Joint Managing Director, Biocon Ltd.
  5. Mr. Manni Kantipudi,CEO, GVK Biosciences Ltd.
  6. Mr. Prabhat Agarwal,CEO, Alkem Labs Ltd.

India’s Most Admired & Valuable Dental Clinic 2016

And the Nominees are

  1. MyDentist
  2. Clove Dental
  3. Axiss Dental
  4. Dentistree
  5. Smile Merchant Dental Clinic
  6. Partha Dental Hospital

India’s Most Valuable & Admired Health Insurance Company 2016

And the Nominees are

  1. Star Health and Allied Insurance Co Ltd
  2. Apollo Munich Health Insurance
  3. Max Bupa Health Insurance Company Ltd
  4. Vidal Health TPA Services
  5. Religare Health Insurance Company Limited
  6. Reliance General Insurance Company Limited

India’s Most Promising Eye Care Hospital 2016

And the Nominees are

  1. Dr Agarwal’s Eye Hospital
  2. Eye – Q Super Specialty Eye Hospital
  3. Aravind Eye Hospitals
  4. Nethradhama Superspeciality Eye Hospital
  5. L V Prasad Eye Institute
  6. Asian Eye Hospital and Lasik Laser Institute

India’s Most Promising & Valuable Trichology clinics 2016

And the Nominees are

  1. Oliva Skin & Hair Clinic
  2. Dr Madhu’s Advanced Hair Transplant Centre
  3. Richfeel Trichology Center
  4. Hairline International
  5. Dr.A’s Clinic Hair Transplants and Hair Loss Treatments
  6. Angel’s Hair Skin & Bodycare.

India’s Most Promising Face in Diet & Nutrition 2016 

And the Nominees are

  1. Ms.Rujuta Diwekar,Nutritionist
  2. Ms.Shonali Sabherwal,Founder Soulfood.
  3. Ms.Sonia Narang,Founder,Sonia Narang’s Diet & Wellness Clinic
  4. Ms.Tripti Gupta, Founder, Ipink.
  5. Ms.Kinita Kadakia Patel, Founder, MEALpyramid
  6. Ms.Anshu Malik, Nutritionist

India’s Most Promising Home Healthcare Service Provider 2016

And the Nominees are

  1. India Home Health Care (IHHC)
  2. HealthCare at HOME India
  3. Portea
  4. Care 24
  5. Homital Medcare
  6. TriBeCa Care

Dynamic Entrepreneur of the year 2016

And the Nominees are

  1. Mr.Shikhar Malhotra,Vice Chairman, HCL Healthcare Ltd
  2. Mr. Amit Burman, Vice Chairman,Dabur India Ltd.
  3. Mr.P.Sarath Chandra Reddy, Director, Aurobindo Pharma Ltd.
  4. Dr. Akshay Batra,Managing Director, Dr. Batra’s
  5. Mr.Amit Bakshi, CMD, Eris Lifesciences Pvt. Ltd.
  6. Mr. Shriram Vijayakumar, MD  & CEO,  DaVita India

Dynamic Enterprise of the Year 2016

And the Nominees are

  1. Quest Diagnostics India Pvt Ltd
  2. Thyrocare Technologies Ltd
  3. Healthcare Global Enterprises Ltd
  4. Sygene International Ltd
  5. Marksans Pharma Ltd
  6. GreenSignal Bio Pharma Limited

Innovative Woman CEO of the year 2016

And the Nominees are

  1. Ms. Anuradha Acharya, CEO, Ocimum Bio Solutions and Mapmygenome
  2. Ms. Rupali Basu,President and CEO, Apollo Gleneagles Hospitals, Kolkata
  3. Ms. Anju Gupta Kaudanya, MD & CEO, Novo Medi Sciences Pvt. Ltd
  4. Ms. Terri Bresenham President & CEO, Sustainable Healthcare Solutions, GE Heathcare
  5. Ms. Nidhi Saxena, CEO, Zoctr Health Private Limited
  6. Ms. Meena Ganesh, CEO and MD Portea medical.

Innovative Face in Cosmetic Dermatology 2016

And the Nominees are

  1. Dr.Sirisha Singh, Director and Sr Consultant Dermatologist, The Skin Center
  2. Dr.Priti Shukla, Founder & Consultant Plastic and Cosmetic surgeon,Ambrosia Clinic
  3. Dr.Sunaina Hameed, Medical Director, Skin.Health Advanced Dermatology Center
  4. Dr. Chiranjiv Chhabra, Founder & Cosmetic Dermatologist, Skin Alive
  5. Dr Deepali Bhardwaj,Founder & Cosmetic Dermatologist, Skin & Hair Clinic
  6. Dr. Simal Soin, Founder & Cosmetic Dermatologist,Aayna

Pharma Professional of the Year 2016

And the Nominees are

  1. Mr.K.G. Ananthakrishnan,Managing Director, MSD Pharmaceuticals India
  2. Mr.Melvin D’Souza,Managing Director, Novo Nordisk India
  3. Mr.Raghu Kumar,Managing Director at Allergan India Pvt Ltd
  4. Mr.Rami Reddy Gundala, Managing Director, Adcock Ingram Limited
  5. Mr.N.Govindarajan,Managing Director, Aurobindo Pharma Limited
  6. Mr.Maturin Tchoumi, Managing Director at Roche India Ltd.

Innovations in Healthcare Solutions 2016

And the Nominees are

  1. GE Healthcare India
  2. Philips Healthcare  India
  3. Johnson & Johnson India Medical
  4. Siemens India Healthcare
  5. Transasia Biomedicals Ltd
  6. Medtronic India

Emerging Company of the Year 2016

And the Nominees are

  1. Vyome Biosciences Private Limited
  2. Aelius Pharma Pvt. Ltd.
  3. Oaknet Life Sciences Private Limited
  4. Novo Medisciences Ltd
  5. Bioderma India
  6. Akriti Pharmaceuticals Pvt. Ltd

Pharma Leader Executive of the Year 2016

And the Nominees are

  1. Mr.G. Sathya,Managing Director,Galderma India Pvt. Ltd
  2. Mr.Ashish Kumar,Managing Director,Schwabe Pharma
  3. Mr.Neeraj Garg,CEO,Apollo Health & Lifestyle
  4. Mr.Amal Kelshikar,Country Head & General Manager, Abbott Nutrition
  5. Mr.Ambarish Chatterjee,General Manager,Laboratorie Bioderma
  6. Mr.Naz Haji,Managing Director,India,QuintilesIMS

Healthcare Start-Up Company of the Year 2016

And the Nominees are

  1. Netmeds Marketplace Limited
  2. Nightingales Home Healthcare India
  3. Neurosynaptic Communications Pvt., Ltd.
  4. Relisys Medical Devices
  5. BabyChakra
  6. MedGenome

India’s Most Promising Hospital of the Year 2016

And the Nominees are

  1. Sahyadri Hospitals
  2. Kovai Medical Centre & Hospital
  3. Cloudnine
  4. Sunshine Hospitals
  5. Kohinoor Hospital
  6. MaxCure Group of Hospitals

Dynamic Women Entrepreneur of the Year 2016

And the Nominees are

  1. Ms.Zoya Brar,Managing Director,Core Diagnostics Private Limited
  2. Dr.Mala Raj,Managing Director, Firm Hospitals
  3. Ms.GarimaTripathi, CoFounder Care24
  4. Ms.Namrata Bajaj, Director, Bajaj Healthcare Limited.
  5. Dr.Reema Das Mallik,Director And Founder, Illumis Aesthetic Clinic
  6. Dr.Radhika Reddy, Founder, Angel’s Hair Skin & Body Care

Clinical Leader of the Year 2016

 And the Nominees are

  1. Micro Therapeutic Research Labs
  2. Lotus Labs
  3. Accutest Research Laboratories
  4. Veeda Clinical Research
  5. Algorithm Informatics
  6. JSS Medical Research

 Woman Healthcare Leader of the Year 2016

 And the Nominees are

  1. Ms.Ranjeeta Vinil, Founder Director, Saarathi Healthcare Pvt Ltd
  2. Ms.Vanaja Krishnan, Managing Director, George Clinical, India
  3. Ms.Deepthi Anand,Founder-CEO, Valencia Nutrition Private Limited
  4. Ms.Aditi Hazra-Ganju, Co-Founder at Mirai Health
  5. Dr.Saral Thangam, CEO & Managing Director, Norwich Clinical
  6. Ms.Shehnaz Vakharia, Director, ADAMAS Clinical Quality Consulting Pvt Ltd

Pharma leaders power brand awards will also be conferred to the deserving companies & individual titles in more than 30 categories in the 9th annual pharmaceutical leadership awards 2016 in a glittering award night.

 

India @ 70, Patient First Need Surgical Strikes on Indian Pharma & Healthcare Sector !

India @ 70, Patient First

Need Surgical Strikes on Indian Pharma & Healthcare Sector !

Satya Brahma*

Pharma Leaders Power Brand Awards (PLPBA®) is a top-ranked, global healthcare Awards meant to motivate & recognize the shining stars of the Indian pharma & healthcare industry developed by Network 7 Research’s team & its team of talented researchers with a robust selection process & backed by years of Pharma Leaders experience in pioneering healthcare innovations through creative communications, initiatives & leadership drive. By leveraging the power of leadership to drive results that matter most to Pharma Leaders Professionals, Pharma Leaders Awards have been trendsetters transforming individual leaders, teams, organizations and pharma scientists. Pharma Leaders’s array of cutting-edge healthcare solutions is steeped in extensive research and experience gained from working with hundreds of thousands of leaders at all levels in different aspects of the fields. Ranked among the asia’s top healthcare leadership destination where talent meets with healthcare innovators, Pharma Leaders Power Brand Awards are much sought after healthcare titles & pharmaceutical healthcare recognitions in the industry today where conventional norms are sometimes broken to give space to budding & unsung healthcare leaders who are often seen performing tirelessly much from the media glare, under tough & challenging conditions making our country proud.

The Theme of the 9th Annual Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards is aptly coined as “India @ 70, Patient First”. In an era where companies buy companies, brands acquired, collaborations formed, revenue models restructured, leadership strategies revamped, the brand india pharma is on the sound footing today. However, Healthcare innovations is meaningless unless access & affordability to the end user, the patients!.Patient First is thus the real need of the hour where 70% of Indian population can get medicines at affordable price & insurance is covered to all & not just to few pockets.

In a country where more than 70 % of 1.3 billion populations are still deprived of basic healthcare access & insurance, I wonder how we can discuss our competence as a global power-house despite our defense capabilities. Healthcare too is a very important wing like defence & there should be no second opinion on our priorities!.It is therefore high time the present dispensation at the central government should discuss comprehensive healthcare reforms by calling a special session of parliament to pass the bill that India has been waiting over the 70 long years encompassing total healthcare benefits through a universal healthcare policy where affordable medicine & quality healthcare & access are practiced in letter & spirit rather than mere sloganeering. Prime Minister Narendra Modi has been voted to power in india after a historic elections in 2014, must understand that people of india voted decisively to the present establishment because of Modi’s reputation in good governance & people centric policy, in no way people will listen to the promises that can be made in achieving the healthcare mission in the pretext of 2019 general election if voted to power again. Since 1947, successive ruling parties at the centre have failed to deliver the long standing demands of “healthcare for all”. Indeed, we are at the threshold of historic moments in present day where we can shape the future, empower the patients through healthcare access & help building a healthy nation.

Against the backdrop of the present state of healthcare affairs of the country, Pharma Leaders, asia’s most analytical new media in healthcare communication is hosting a historic summit currently in its 9th successful annual editions under the theme “Pharma Leaders 2016 : India @70, Patient First” on Friday at Hotel Sahara Star, Mumbai, the 23rd December 2016. More than 400 leading stalwarts from the industry, veteran healthcare leaders, politicians, policy makers, social activists, change agents will gather to witness the most awaited event of the calendar year. Nation’s top leaders & companies will also be conferred with pharma leaders power brand annual awards in more than 30 specialized categories. Leading lights of the pharmaceutical & healthcare sector will address at the summit on topics of tremendous significance followed by heated panel discussions.

Access to healthcare is influenced by whether or not people have health insurance, whether there is an adequate health provider workforce, how long the travel distances are to reach providers, and whether there are language and cultural barriers, and cost.  Barriers in any of these areas can result in lack of access, delays in care, higher costs and worst outcomes. People without health insurance or without a primary care provider are less likely to get timely treatment, screening and preventive services, and are more likely to use costly emergency services resulting in higher emergency room and higher hospitalization rates which are witnessed in our country. This must be addressed with utmost seriousness. Intellectual property rights (IPR), better patent protection, locking horns on compulsory licensing, stricter trademark enforcement, pricing, regulatory frameworks are some of the areas that India must give a serious look. It is high time we must set our house in order before lecturing outside. Easing of business is a big area that will open up global players to look at India safely.

Indian pharmaceutical companies have ranked low at 19th position with an overall score of 59 out of 100 among in the Biopharmaceutical Competitiveness & Investment (BCI) Survey. The total spending on healthcare is around 4 per cent of GDP, while the government spends less than 1 per cent of the GDP on health, even as the insurance penetration remains low (industry experts talk of less than 20 per cent of the population having health insurance).

The World Health Organization also ranks India at a low 112 level out of 190 countries on healthcare systems. Even countries with demographics similar to India, seem to have fared better. India, despite being armed with a domestic industry that has made the country a leading producer of low-cost medicines in the world, is still having to grapple with issues of seasonal diseases like Swine Flu, which resulted in numerous deaths despite an available vaccine. The same was the case with some region-specific and cyclic ailments like Chikungunya and Dengue. Experts point out that India still lacks a stockpiling policy on vaccines (in cases where they are available) and in cases where the vaccines are not available, there is lack of government push or a national focus to aid research in select therapy areas.

The growth story of the Indian pharma industry into a mammoth industry is an impressive one marked with numerous important turning points. These turning points have typically stemmed from the issues faced by the industry and have changed the nature and mechanisms of the industry, and to a large extent have sculpted the trends in the industry.

The Indian pharmaceutical industry is expected to be among the top 3 pharma markets by 2020 on back of incremental growth, says an Indian Brand Equity Foundation (IBEF) report. The industry, currently valued at near USD 26 billion, is expected to reach USD 55 billion in the next four years. From 2005-16, the industry has seen a growth of 17.90 percent CAGR. The market size has expanded to USD 36.7 billion in 2016 from USD 6 billion in 2005. India is the largest provider of generic drugs and has 20 percent global exports in terms of volume. In recent times, the pharmaceutical sector had taken a beating over the stricter regulatory actions from the United States Food & Drug Association (USFDA) and a subdued global economy. Indian pharma companies will need to adapt their business models, organizations and processes to align with new environments. Leading global companies have adopted multiple levers to tap emerging markets for product portfolios, sourcing or innovation. However their ability to understand these markets and drive revenue growth will be the key determinant of the extent of their investment and participation.

India has skilled workforce and competent technical expertise in comparison to its peers. India has the second largest number of USFDA approved manufacturing plant outside the US and has 2,633 FDA approved drugs. While growth opportunities for the sector are expected to rise, growing competition and entrance of new players will be a major challenge for pharmaceutical companies. The bigger players with strong financial hold too will be a concern. Also, tightening of norms by regulatory bodies will be a challenge as the companies will have to improve and remain at the top-of-their-game.

A ban on hundreds of medicines in India because of concerns over health risks has brought into focus the drastic need for tighter regulation of the country’s multibillion dollar pharmaceutical industry. India’s government recently has put a ban on the manufacture and sale of more than 340 fixed dose combination drugs, resulting in major pharmaceutical firms including Pfizer’s Indian division and Cipla taking the case to Delhi high court in an effort to overthrow the move.

India’s pharmaceutical industry is ranked third globally in terms of volume and 13th in value, accounting for 10 per cent of production worldwide, according to a report by The Associated Chambers of Commerce of India (Assocham) and Yes Bank. It says that the industry in India is expected to grow to $48 billion by the financial year between April 2017 to March 2018, expanding at a compound annual growth rate of 14 per cent.India’s pharmaceutical industry thrives on the production of cheap generic drugs, which are copies of off-patent medicines. India is estimated to produce one-fifth of generic medicines globally.

I see India as a potential pharmacy hub for the world, “If we make a few changes in the way we do and manage business in India, we can accelerate that process & confident that India could have a $300bn pharmaceutical industry by 2030.Technology will be a game changer in the manner in which healthcare services will be delivered in India. The private sector will be the major driving force behind technology adoption in the Indian healthcare segment. To optimize costs and effectively manage operations, IT solutions will become an integral part of process management, patient care and the management information system (MIS) in hospitals. With the health insurance sector poised for major growth in the coming decade, increasing demand from this sector for more efficient systems for storage and retrieval of information will put pressure on hospitals and other healthcare providers to imbibe technology to modernize existing infrastructure.

The author is Chairman  & Editor-In-Chief of Pharma Leaders.

 

#PharmaLeaders

#PharmaLeaders2016

#PharmaLeadersPatientFirst

#PharmaSummit

#PharmaLeadersAwards

#23rdDecemberWithsatyaBrahma

#HealthcareForAll

India’s Top 10 Powerful Influential Pharma Leaders 2016 List

India’s Top 10 Powerful Influential Pharma Leaders 2016 List

Prof Ramesh Mishra*

Pricing, Regulatory Hurdles & OTC Market remain the key focus at Pharma Leaders 2016 Research Report. Dilip Shanghvi, Pankaj  Patel, Samprada Singh, R.C.Juneja,Dilip Surana  are among top 10 Powerful Indian Pharma Leaders 2016

pl-super

Indian Pharmaceutical Industry has evolved as a dominant & powerful sector since india’s seventy years of independence & yet the industry remains largely fragmented with top 100 players in complete command of dominance. Today these top 100 companies have more than 80 % of the market share out of which majority players are domestic companies. MNC’s in india has grown significantly but their growth of late has been outpaced by the aggressive Indian companies. Pharma Leaders, India’s first media to interview more than 500 leaders of the pharmaceutical industry has brought out this special report titled “India’s Top 10 Powerful Pharma Leaders 2016” based on a credible research inputs followed by interviewing & interacting with all the stakeholders of the pharmaceutical industry. The key findings of the report other than the selection of the top 10 Leaders are as the following.

1

3

4

g-m2m_pharma_web healthcare-august-2015 healthcare-nov-2015 jpg pharmaceuticals-nov-2015

Using comprehensive interview, survey, and observational data from 100 successful Pharma Leaders using the competitive market analysis, the researchers found that our findings on the top 10 influential Powerful Pharma Leaders of 2016 — defined as aggressiveness, assertiveness, and confidence — were also able to “excel in tough conditions considered very risky”.

Key Findings:

  • Indian Players are likely to dominate the market till 2025
  • Top 100 Domestic Players may join hands together through co-marketing, R&D & brand acquisitions.
  • Top privately held companies will go for public (IPO) in next 2 years, till 2018
  • Top Brands will be up for grabs with premium
  • Generics will be the key drivers for growth
  • Top 100 companies will set up manufacturing facilities to fuel growth engines.
  • Second generation Leaders will take over the Leadership Mantles.
  • OTC segments will be the part of top 40 companies out of 100.
  • Field Force of top 30 Companies will double by 2018.
  • Exports will be the key focus.

India’s Top 10 Powerful Pharma Leaders 2016

Overview

There are many organizations who are involved in rankings based purely on turnovers or profits or purely on financial background. While Pharma Leaders research desk purely respects the mechanism of selection process & the judging criteria, we have given considerable emphasis on the trust & branding factors & the credible face of the leadership steering the company’s growth engine & putting patients first. In this feature survey, we have only taken the Indian companies & not included the MNC’s as the scope of the study research involved included the role of visionary leadership, team buildings, brand buildings, CSR & Indian perspective of looking leadership. Network 7 Media Group, the research wing of Pharma Leaders undertook the responsibilities of finding the top 10 Powerful Pharma Leaders of 2016.

The primary objective that our experts looked at is Brand Equity & Leadership Dominance. Indian pharma market is dominated by a strong patronage of brands by the different stakeholders; the research paper looked into great details as how the person concerned has been able to influence the society & industry at large. Corporate Social Responsibilities (CSR) also was one of the top focus while determining the leadership role of the top 10 influential Pharma Leaders of 2016.

Selection Process & Methodology 

 Unlike other organizations, Pharma Leaders being a media house relied purely on the external patronage & opinions of the key stakeholders on determining the top 10 Leaders.The sample size of the analysis included all 29 states & 7 Union territories, both urban & rural areas on a pan india basis. More than 5000 opinion makers were consulted which included the followings.

  • Contemporary Peers
  • Past Leadership
  • Distribution Agents
  • Pharmacists
  • Doctors
  • Policy Makers
  • Govt Agencies
  • NGO’s
  • Image Consultants
  • Medical Representatives
  • Consultants
  • Market Research Analysts

……………………………………………………………………………………………………………

The Top 10 List

  1. Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd
  2. Desh Bandhu Gupta, Chairman, Lupin Limited
  3. Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd
  4. Y.K. Hamied,Non-Executive Chairman,Cipla Ltd
  5. Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila
  6. Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd
  7. Samprada Singh, Chairman Emeritus,Alkem Labs Ltd
  8. Dilip Surana, CMD, Microlabs Ltd
  9. R.C.Juneja, Chairman, Mankind Pharma Ltd
  10. Habil. F.Khorakiwal, Chairman, WockhardtLtd

dilp

Mr. Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd

The current market capitalisation of Sun Pharma  stands at Rs 184,441.59crore.

Mr. Dilip Shantilal Shanghvi founded Sun Pharmaceutical Industries Limited in 1982 and served as its Managing Director since May 29, 2012. Mr. Shanghvi served as the Chairman and Managing Director of Sun Pharmaceutical Industries, Inc. He has been the Chairman and Managing Director of Sun Pharma Advanced Research Company Limited since March 1, 2012. He has wide extensive industrial experience in the Pharmaceutical industry. He has been the Chairman of Taro Pharmaceutical Industries Ltd., since July 18, 2013. Mr. Shanghvi has been the Chairman of Caraco Pharmaceutical Laboratories Ltd. since 1997. Mr. Shanghvi served as the Chairman of the Board of Sun Pharmaceutical Industries Ltd until May 28, 2012. since 1999. He served as the Chairman of the Board of Taro Pharmaceutical Industries Ltd. from September 20, 2010 to April 18, 2012. He has been a Director of Sun Pharma Advanced Research Company Limited since March 1, 2006. He serves as a Director at Sun Speciality Chemicals Pvt. Ltd., Sun Resins & Polymers Pvt. Ltd., Sun Fastfin Services Pvt. Ltd., Sun Petrochemicals Private Limited, SPARC Bio-Research Private Limited, Sun Pharma Global Inc., British Virgin Island, Sun Pharma De Mexico SA DE CV, SPIL De Mexico SA DE CV and Shantilal Shanghvi Foundation. He serves as its Promoter Executive Director of Sun Pharmaceutical Industries Ltd .He served as a Director of Taro Pharmaceutical Industries Ltd. until April 18, 2012. Mr. Shanghvi is graduate in commerce from Kolkata University.

Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company, manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental, and nutritionals. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India


logo

Dr Desh Bandhu Gupta, Chairman, Lupin Limited

The current market capitalisation of Lupin stands at Rs 67,437.26 crore.

Dr. Desh Bandhu Gupta is Chairman at Lupin Ltd. He is on the Board of Directors at Zyma Laboratories Ltd., Rahas Investments Ltd., Visiomed Investments Pvt. Ltd., Lupin Holdings Pvt. Ltd., Lupin Investments Pvt Ltd., Lupin International Pvt Ltd., Polynova Industries Ltd., Lupin Properties Ltd., Novamed Investments Pvt. Ltd., and Synchem Investments Pvt. Ltd.Mr. Gupta was previously employed as an Associate Professor by Birla Institute of Technology & Science. In 1968 at 30 years of age, Desh Bandhu Gupta started off with was a very ambitious dream of manufacturing drugs of national priority. The aim was to fight life threatening diseases with a business capital of 5000 Indian Rupees that he borrowed from his wife. He started his working career as Associate Professor at Birla Institute of Sciences and Technology, but never seemed satisfied with his contributions to the country and society. With an initial investment coming his way in the form of loan from the Central Bank, he set up the manufacturing unit in Mumbai and attained this uphill task he had set of first year; Sales target of 5 lakh Indian Rupees.

Lupin Limited, a pharmaceutical company, develops, manufactures, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiology, central nervous system (CNS), diabetes, anti-asthma, gastro- intestinal, COPD, and gynecology; and APIs for use in therapeutic areas of cephalosporins, cardiovascular, and anti-TB. The company also develops drug delivery technologies; and biosimilars for various therapeutic indications, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women’s health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.


236139-satish1

Mr. Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd

The current market capitalisation of Dr. Reddy’s Labs stands at Rs 54,502.30crore.

Mr. Kallam Satish Reddy, B.Tech., M.S., serves as a Member at Management Council at Dr. Reddy’s Laboratories Ltd. Mr. Reddy served as the Managing Director of Dr. Reddy’s Laboratories Ltd. and has been its Chairman since May 13, 2014. Mr. Reddy served as Executive Director in charge of the manufacturing operations of active pharmaceutical ingredients and formulations, research and development activities and new product development at Dr. Reddy’s Laboratories Ltd. since 1993 and served as its Chief Operating Officer. He served as Vice Chairman of Dr. Reddy’s Laboratories Ltd. from March 30, 2013 to May 13, 2014. He has been a Whole Time Director at Dr. Reddy’s Laboratories Ltd. since January 18, 1993, Director of Diana Hotels Limited as well as certain of Dr. Reddys Laboratories Ltd.’s subsidiaries. and also served as Director at Dr. Reddy’s Laboratories Ltd. He served as Director of Cheminor, and is a member of the Indian Institute of Chemical Engineers. Mr. Reddy has a Master of Science degree in Medicinal Chemistry from Purdue University in 1990 and a Bachelor of Technology degree in Chemical Engineering from Osmania University in 1988.

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (NCEs) for dermatology and neurology therapeutic areas. It also engages in the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as metabolic disorders, and pain and inflammation; and has a portfolio of in-licensed patented dermatology products. As of March 31, 2016, this segment had 19 active products in development programs pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. It has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreements with Merck Serono and Amgen. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

dsc-0013-edited-274x186

Dr. Y.K. Hamied,Non-Executive Chairman,Cipla Ltd

The current market capitalisation stands at Rs 48,590.40crore.

Dr. Yusuf Khwaja Hamied, also known as YK, served Managing Director of Cipla Limited from August 1, 2008 to March 31, 2013. Dr. Hamied joined the Cipla Limited as an officer-in-charge of research and development in 1960. He is well-respected for his vast and varied experience of 48 years not only in India but also internationally. He has done research work under Lord Todd FCS, a Nobel Laureate. He is a highly qualified and Eminent Chemist. He has been the Chairman at Cipla Limited since April 1, 2013. He serves as Non-Executive Non Independent Director at Cipla Limited. He obtained a Doctorate in chemistry from Cambridge University.

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals, including companion, equine, livestock, poultry, swine, and aqua products. In addition, it offers inhaled medication and devices comprising dry powder inhalers, metered-dose inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices; and personal products. The company also exports its products to Africa, the Middle East, Latin America, the Asia Pacific, China, Russia, and internationally. Cipla Limited was founded in 1935 and is based in Mumbai, India.


pankaj-patel

Mr.Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila

The current market capitalisation of Cadila Healthcare stands at Rs 40,248.44 crore.

Mr. Pankaj R. Patel, M.Pharm, serves as the Chairman of Cadila Healthcare Limited and has been its Managing Director since September 1, 2006. Mr. Patel serves as the Chairman and Managing Director of Zydus Animal Health Limited, a subsidiary of Cadila Healthcare Limited and he is the guiding force behind its fast tracked growth. He has been Senior Vice President at Federation of Indian Chambers of Commerce and Industry since December 2015. He serves as the Regional Representative to the South East Asia Region of WHO. He over 35 years of professional experience and spearheads the affairs of Zydus Cadila. He served as the Non Executive Chairman of Zydus Wellness Limited from August 2009 to July 14, 2014. He serves as a Non-Executive Independent Director of Nirma Limited. He has been an Independent Non-Executive Director of Torrent Power Limited since September 29, 2006 and Cadila Healthcare Limited since August 15, 1995. He served as a Non Executive Director of Cipla Limited from March 5, 2008 to September 2014. He served as a Director of Zydus Wellness Limited from April 27, 2009 to July 14, 2014. He served as a Director of Dialforhealth India Limited, Zydus Pharmaceuticals Limited, BAAP Diagnostics Limited, Zydus Technologies Limited, Vadilal Chemicals Limited and Kafnavati Club Limited. He served as a Director of Onconova Therapeutics, Inc. He served as a Director at Gujarat Themis Biosyn Ltd. from January 15, 1992 to October 25, 2008. He served as Additional Director of Nirma Limited since October 28, 2006. He has been the President of Gujarat Chamber of Commerce & Industry since 2006. He is involved in many charitable activities including as a Trustee of Shri. B.V. Patel Pharmaceutical Education and Research Development Center in India. He is associated with various associations like Federation of Indian Chamber of Commerce & Industry, Indian Drug Manufacturers Association, Indian Pharmaceutical Alliance, Basic Chemicals, Pharmaceuticals and Cosmetics Export Promotion Council (CHEMEXIL) etc. He is actively involved in various institutions and serves on the advisory committees and academic councils of leading pharmaceutical colleges and management institutes. He has published over 50 research papers. For his innovative business practices, he was conferred with the award “Pharma Man of the Year” by the Federation of Indian Industry and Economists in 2004. The World Pharmaceutical Frontiers’ in their global raking of the most influent people in the filed of healthcare had featured Mr. Patel in their ‘First Pharma 40’ list. He is one of the most successful and highly respected Pharma entrepreneurs in India. He has a Masters in Pharmaceuticals and Pharmaceutical Technology. He is a Science graduate of Bombay University. He is a Law graduate from the Bombay University.

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company is developing a pipeline of 20 biologics comprising 14 biosimilars and 6 novel biological products; and new drugs in cardio-metabolic disorder, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company is developing vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, HPV, and combination vaccines. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.


glenn-saldanha_0

Mr. Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd

The current market capitalisation of Glenmark stands at Rs 26,152.76 crore.

Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Ltd. since 2001. Mr. Saldanha serves as the Chief Executive Officer of Glenmark Pharmaceuticals S.A. He has worked for Eli Lilly in the U.S and was a Management Consultant with Price Waterhouse Coopers. His Services have been used by Smithkline Beecham, Rhone Poulenc Rhorer, Astra, Merck and Johnson and Johnson, among others. He has 15 years of experience in Pharmaceutical Industry. He has been the Chairman of Glenmark Pharmaceuticals Ltd. since May 10, 2011. Mr. Saldanha served as Chairman of Glenmark Generics Ltd. He has been a Director of Glenmark Pharmaceuticals S.A. since 1998. He served as Independent Director of Talwalkars Better Value Fitness Ltd. since October 2009 until November 22, 2011. He was awarded the Watumall Foundation Award for overall excellence. Mr. Saldanha holds a B.Pharm. from Bombay University and an MBA from New York University’s Leonard N.Stern School of Business (US).

Glenmark Pharmaceuticals S.A operates as a pharmaceutical research and development company. It engages in clinical and non-clinical development of the group’s new chemical entity programs. The company’s products include Oglemilast, a PDE-4 inhibitor for asthma; GRC 8200, a DPP-4 inhibitor for diabetes; GBR 401, an anti-CD19 monoclonal antibody; CB-1 antagonist for obesity; and GBR 500, a therapeutic monoclonal antibody for chronic autoimmune disorders. The company has a strategic global collaboration with Sanofi. The company was founded in 2004 and is based in Neuchâtel, Switzerland. Glenmark Pharmaceuticals S.A operates as a subsidiary of Glenmark Pharmaceuticals, Ltd.


samprada

Mr. Samprada Singh, Chairman Emeritus,Alkem Labs Ltd

The current market capitalization of Alkem stands at Rs 21,927.62crore.

Mr. Samprada Singh founded Alkem Laboratories Limited in August 8, 1973 and has been its Chairman Emeritus since April 1, 2015. Mr. Singh served as the Chairman of Alkem Laboratories Ltd. Mr. Singh is one of the most respected and successful entrepreneurs of the Indian Pharmaceutical Industry. The growth of Alkem and the success of Mr. Singh is most amazing since Mr. Singh started this organization from scratch and through tremendous dynamism, vision and leadership has brought it to the top of the Indian Pharmaceutical Industry today. To Mr. Singh goes the major credit of seeing Alkem through its various stages of progress from the beginning, till today, when Alkem is a name to reckon with in the Indian Pharmaceutical Industry. In 1953, Mr. Singh made a small beginning as a Retail Chemist. In 1960, he started a business of Pharmaceutical distribution in Patna under the banner of ‘Magadh Pharma’. Due to his sincerity, hard work and affable nature, Mr. Singh was able to acquire the distributorship of several renowned multinationals and soon, successfully built up a sound distribution network in the eastern region of India. Realizing the limitations of expanding in the distribution business, in the year 1972, Mr. Singh became the founder Director of a Bombay based Pharmaceutical company. Mr. Singh selected healthcare and pharmaceuticals as his focus area as an entrepreneur. From the very early days of Alkem Laboratories Ltd., Mr. Singh always emphasized the need for excellence in products, personnel, quality and service. He has been a Non Executive Director of Alkem Laboratories Limited since August 08, 1973. In the year 2004, Mr. Singh was honoured with the prestigious “Life Time Contribution Award” by the Express Pharma Excellence Awards, which is reckoned by many as the Oscar of the Indian Pharmaceutical Industry. In June 2002, Mr. Singh received yet another award. The ‘Medicine Update Lifetime Achievement – Health Care Award’ went onto honour his achievement in the pharmaceutical industry as one of it’s most successful entrepreneurs. In October 2000, Mr. Singh was conferred upon with the ‘Life Time Achievement Award’ by Pharma Business and Technology, one of the most distinguished and respected entrepreneurs of the Indian Pharmaceutical industry. During Mr. Singh four years as an undergraduate, Mr. Singh exhibited his dynamism through various student activities. Mr. Singh entered Gaya College, Patna University in 1946 to specialize in Commerce. He received a B.Com. Degree from Patna University in 1950. Mr. Singh holds a post graduate degree in Political Science.

Alkem Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells pharmaceutical and neutraceutical products. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and neutraceuticals in acute and chronic therapeutic areas, such as anti-infective, gastro-intestinal, pain and analgesics, vitamins/minerals/nutrients, cardiac and diabetology, gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants. It offers its products to various hospitals, government institutions, and medical institutions through a network of 7,000 stockiest in India and internationally. Alkem Laboratories Limited was founded in 1973 and is headquartered in Mumbai, India.


dilip-anand-surana_416x416

Mr. Dilip Surana, CMD, Microlabs Ltd

Privately held Company

Mr. Dilip Surana son of Late Shri G. C. Surana (Founder of Micro Labs Limited) joined the family business in 1985 at a young age of 21 years, and  rapidly absorbed the nuances of Corporate Management that grew the company rapidly into a global pharmaceutical enterprise specializing in life saving medicines. His early years in industry were marked by distinguished accomplishments and thus steering Micro Labs among the top ranking companies in the pharma sector. The AWACS ranking for the company has improved from over 100 in 1985 to 18 as on 2014.  Under his leadership, the company established world-class state-of-the-art research and manufacturing facilities covering Active Pharmaceutical Ingredients (APIs) and finished dosage forms as well as infrastructure for new drug discovery. He instilled the most stringent quality standards in his pharmaceutical enterprise. As a result, Micro Labs has to its credit, all the international regulatory approvals including US FDA, UK MHRA, Australian TGA etc., reflecting the high standards of quality and regulatory compliance of research and manufacturing facilities. He pioneered the concept of specialty – wise focused divisions in the Indian Pharmaceutical Industry and established various divisions that cater to special therapeutic segments in chronic disease management. He is a regular participant in various international seminars and summits relating to Pharma industry. He is instrumental in inducting Senior Pharma veterans in the company, to bring in the much needed professionalism in the company. Recognizing the dynamism and contribution of Mr. Dilip Surana to the Pharmaceutical Industry, he has been honored as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the ‘Great Son of karnataka’ by Governor of Karnataka his excellency HR Bhardwaj in 2011, honoured as ‘Most Dynamic Entrepreneur of the Year’ 2013 and ‘Entrepreneur of the year’ 2014.

Micro Labs Ltd. manufactures pharmaceutical products. It offers products ranging from oral solids and liquids, topicals to injectables in pediatric, gynecology, ophthalmology, gastro, orthopedic, nephrology, neuro psychiatry, dermatology, diabetology, general surgery, ENT, dental, neurology, cardio diabetic, dyslipidemias, hypertension, metabolic syndrome, arrhythmias, and veterinary areas. The company markets branded generics through own and outsourced distribution networks in India and internationally. Micro Labs Ltd. was founded in 1973 and is based in Bengaluru, India. It has subsidiaries and representative offices in the United Kingdom, the Russian Federation, Vietnam, Ukraine, and Mexico. The company has manufacturing plants in Hosur, Bengaluru, Pondicherry, Goa, Baddi, and Sikkim, India; and the United Kingdom, Canada, and South Africa.


Corporate Portrait Photography for Mankind Pharma Group of all the Directors, Chairman, Managing Director. Pictures were shot at ManKind Pharma Corporate office in Delhi in the month of December 2011 CEO Portrait Shoot by Guru Dutt & Sharmila representing Guru Dutt Phtography/ Prashanti Photography.

Privately held Company

Mr R. C. Juneja, the founder of Mankind Group, is one of the most reputed business leaders in the pharmaceutical industry. He laid the foundation stone of Mankind Pharma in 1986, and the company became a legal entity in 1991. Mankind Group earned its reputation as a fully integrated pharmaceutical company in 1995. In 2011, Mr. Juneja was presented with the ‘India Business Icon (Pharma) Award’ by Network 18.He firmly believes that honesty and transparency go hand-in-hand with business acumen. He also shares his life experiences with the youth and encourages them to come forward and take up new challenges and responsibilities. He revolutionized the Indian pharmaceutical market by inspiring others to follow the trend of providing quality products at an economical price.

Mankind Pharma Limited manufactures pharmaceutical products for antibiotic, antifungal, NSAIDs, gastrointestinal, anthelmintic, cardiovascular, dermal, erectile dysfunction, and other categories. It also offers contraceptive products, over-the-counter medicines, pregnancy detection cards, artificial sweeteners, and other products; and nutritional supplements, cosmetics, anti-infective tablets, anti-diabetic tablets, proton pump inhibitors, anti-allergic tablets, emergency contraceptives, anti-emetic, and other products. In addition, the company provides active pharmaceutical ingredients for various therapeutic areas, such as cardiology, respiratory, neurology, gastroenterology, diabetology, dermatology, ophthalmology, gynecology, and others. It sells its products through a network of stockists, CFAs and CSAs, chemists and medical stores, and doctors. Mankind Pharma Limited was incorporated in 1991 and is headquartered in New Delhi, India. It has operations in Asia, Africa, South-East Asia, and Gulf countries.


khorakiwala-h10

Mr. Habil. F.Khorakiwal, Chairman, WockhardtLtd

The current market capitalisation of Wockhardt stands at Rs 10,060.98crore

Dr. Habil F. Khorakiwala founded Wockhardt Ltd. in 1967 and serves as its Executive Chairman. Dr. Khorakiwala has bee Group Chief Executive Officer at Wockhardt Ltd. since 1967. Dr. Khorakiwala served as the Managing Director of Wockhardt Ltd. until April 2009. Dr. Khorakiwala serves as the Chairman at Wockhardt USA, Inc., and Wockhardt Hospitals Ltd. He serves as the Chairman of Khorakiwala Holdings and Investments Private Limited. He serves as Chairman of Wockhardt Bio AG. He serves as Director of Dartmour Holdings Private Limited. He has been a Director at Wockhardt Hospitals Limited since August 28, 1991. He serves as a Director of Wockhardt Bio AG, Wockhardt Europe Limited and CP Pharmaceuticals Limited. He is an Ex-President of Indian Pharmaceutical Alliance (IPA). He served as a Director of SOFTBPO Global Services Ltd. since August 1, 2006. Dr. Khorakiwala served as an Independent Director of IDream Film Infrastructure Company Ltd from October 26, 2005 to January 28, 2014. He serves as a Vice-President of FICCI and a member of the National Manufacturing Competitiveness Council. Dr. Khorakiwala was the recipient of the Ernst & Young `Entrepreneur of the Year’ Award in 2004 in the category of Healthcare and Life Sciences. He holds Bachelor’s Degree in Pharmacy from Purdue University. Dr. Khorakiwala holds an Master Degree in Pharmaceutical Science from the Purdue University, USA and is an alumnus of the Harvard Business School, USA.

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines in India, the United States, Europe, and other countries. It provides pharmaceutical products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. It develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.

The Author Prof Mishra is Executive Editor of Pharma Leaders.